

Study supports glucocorticoid tapering in patients achieving disease control on tocilizumab

June 12 2019

The results of a randomised controlled trial presented today at the Annual European Congress of Rheumatology (EULAR 2019) demonstrate high levels of treatment success in approximately two thirds of patients despite tapered glucocorticoid (GC) discontinuation, while a small loss of disease control was observed at the total study population level.

"On the basis of our results, we believe that all patients achieving low disease activity or remission with tocilizumab should be offered [glucocorticoid](#) tapering," said Professor Gerd R. Burmester, Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Germany.

Results demonstrate, after 24 weeks, a small but [significant difference](#) in disease activity following GC tapering with a between arm difference of 0.6 DAS28-ESR units (95% confidence interval (CI):0.3-0.9; p

Citation: Study supports glucocorticoid tapering in patients achieving disease control on tocilizumab (2019, June 12) retrieved 4 May 2024 from <https://medicalxpress.com/news/2019-06-glucocorticoid-tapering-patients-disease-tocilizumab.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is

provided for information purposes only.